OncoMatch/Clinical Trials/NCT04585490
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Is NCT04585490 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for non small cell lung cancer.
Treatment: Durvalumab · Carboplatin · Pemetrexed · Paclitaxel · Cisplatin · AVENIO ctDNA Surveillance Kit · Tremelimumab — The purpose of this study is to test whether or not number of circulating cancer cells detected in the blood can be decreased the by combining the standard treatment (durvalumab) with Tremelimumab and additional chemotherapy
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage III
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — definitive chemoradiation for stage III or recurrent disease
must have completed platinum-based chemotherapy and radiation therapy to all known tumor sites (60 Gy +/- 10%)
Must have received: radiation therapy — definitive chemoradiation for stage III or recurrent disease
must have completed platinum-based chemotherapy and radiation therapy to all known tumor sites (60 Gy +/- 10%)
Must have received: anti-PD-L1 therapy (durvalumab) — consolidation after chemoradiation
Must be receiving consolidation durvalumab following completion of radiation and chemotherapy, and less than 32 weeks has elapsed from their first dose of durvalumab.
Cannot have received: investigational product
Received Investigational product as part of another clinical study
Lab requirements
Blood counts
Absolute neutrophil count > 1.0 x 10^9/L (1000/mm3); Platelets > 75 x 10^9/L (100,000/mm3); Hemoglobin ≥ 9.0 g/dL (5.59 mmol/L)
Kidney function
Measured creatinine clearance > 40 mL/min (by 24 hour urine or Cockcroft Gault formula)
Liver function
Serum bilirubin ≤ 1.5 x ULN (except Gilbert's syndrome); AST/ALT ≤ 2.5 x ULN unless liver metastases present, then ≤ 5 x ULN
Absolute neutrophil count > 1.0 x 10^9/L (1000/mm3); Platelets > 75 x 10^9/L (100,000/mm3); Hemoglobin ≥ 9.0 g/dL (5.59 mmol/L); Measured creatinine clearance > 40 mL/min; Serum bilirubin ≤ 1.5 x ULN (except Gilbert's syndrome); AST/ALT ≤ 2.5 x ULN unless liver metastases present, then ≤ 5 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford University · Stanford, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify